ADAPTIVE BIOTECHNOLOGIES COR's ticker is ADPT and the CUSIP is 00650F109. A total of 199 filers reported holding ADAPTIVE BIOTECHNOLOGIES COR in Q2 2020. The put-call ratio across all filers is 0.51 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $6,671,443 | -18.2% | 1,224,118 | +0.7% | 0.10% | -9.8% |
Q2 2023 | $8,156,173 | -21.0% | 1,215,525 | +3.9% | 0.11% | -34.5% |
Q1 2023 | $10,326,862 | -61.0% | 1,169,520 | +24.1% | 0.17% | +13.2% |
Q4 2021 | $26,451,000 | -60.5% | 942,666 | -52.1% | 0.15% | -56.5% |
Q3 2021 | $66,951,000 | -20.1% | 1,969,726 | -3.9% | 0.35% | -15.6% |
Q2 2021 | $83,762,000 | -12.7% | 2,049,963 | -14.0% | 0.41% | -20.5% |
Q1 2021 | $95,988,000 | -31.6% | 2,384,205 | +0.4% | 0.52% | -25.8% |
Q4 2020 | $140,422,000 | +20.5% | 2,374,798 | -0.9% | 0.70% | -2.9% |
Q3 2020 | $116,580,000 | -1.9% | 2,397,279 | -2.4% | 0.72% | -22.7% |
Q2 2020 | $118,786,000 | +87.6% | 2,455,269 | +7.7% | 0.93% | +22.4% |
Q1 2020 | $63,318,000 | +169.5% | 2,279,250 | +190.3% | 0.76% | +211.1% |
Q4 2019 | $23,493,000 | -4.1% | 785,198 | -0.9% | 0.24% | -13.2% |
Q3 2019 | $24,492,000 | -14.3% | 792,621 | +33.9% | 0.28% | -2.4% |
Q2 2019 | $28,581,000 | – | 591,749 | – | 0.29% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Blue Water Life Science Advisors, LP | 3,030,434 | $23,152,516 | 15.55% |
BERYLSON CAPITAL PARTNERS, LLC | 289,726 | $2,213,507 | 6.45% |
Matrix Capital Management Company, LP | 11,572,590 | $88,414,588 | 1.69% |
Pier Capital, LLC | 1,012,401 | $7,734,744 | 1.27% |
VIKING GLOBAL INVESTORS LP | 29,993,708 | $229,151,929 | 1.15% |
Eagle Health Investments LP | 607,860 | $4,644,050 | 1.07% |
Triatomic Management LP | 130,805 | $999,350 | 0.84% |
Aristotle Atlantic Partners, LLC | 1,880,567 | $14,367,532 | 0.80% |
Senator Investment Group LP | 1,000,000 | $7,640,000 | 0.69% |
ARK Investment Management | 9,201,245 | $70,297,512 | 0.61% |